| Multiple Sclerosis |
1 |
1 |
| Biologic Therapy |
0 |
0.73 |
| Monoclonal Antibody |
0 |
0.56 |
| Antineoplastic Drug |
0 |
0.51 |
| Neuromyelitis Optica |
0 |
0.49 |
| Revenue and Practice Management |
0 |
0.46 |
| Immunoglobulin G (IgG) |
0 |
0.39 |
| Hospital |
0 |
0.3 |
| Care and Maintenance of Vision |
0 |
0.25 |
| Plasma |
0 |
0.25 |
| Wound Management |
0 |
0.23 |
| Colorado |
0 |
0.2 |
| Insurance |
0 |
0.2 |
| Massachusetts |
0 |
0.2 |
| Injury |
0 |
0.15 |
| Optic Nerve |
0 |
0.11 |
| Epidemiology |
0 |
0.1 |
| Hiccups |
0 |
0.1 |
| Natural Killer (NK) Cells |
0 |
0.1 |
| Nausea |
0 |
0.1 |
| Nerve |
0 |
0.1 |
| Neutrophils |
0 |
0.1 |
| Spinal Cord |
0 |
0.1 |
| Steroids |
0 |
0.1 |
| Tissue |
0 |
0.1 |
| Healthcare and Medical Technology |
0 |
0.06 |
| Systemic Lupus Erythematosus |
0 |
0.06 |